APRE$0.98+0.00%

Fair $0.98+0.0%

APRE

Aprea Therapeutics, Inc.

Healthcare / BiotechnologyNasdaqCM

$0.98

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.98Fund rank 30/100 · Data gapFallback financials|

SA 1/F

F-Score: 1/9

Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 25% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-12.9M · quality 53.7/100

Data gap 30/100

Bear 5Yn/dn/d

Base 5Yn/dn/d

Bull 5Yn/dn/d

Return 0/100Downside 20/100Model quality 57/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

1/100

Piotroski

1/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 9Warnings: 1unknown: 9

No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific biotech pipeline model required: targets are disabled until product, probability, peak-sales and cash-runway data exists. ROE is -1.0%, below the 5% threshold

Thesis & Journal · APRELocal privado en este navegador · Aprea Therapeutics, Inc.

Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Tesis central

Bull caseBase caseBear case

CatalizadoresRiesgos

Kill criteria

Mi valoración / targetReview date

Sin guardar todavía.

Market Cap

$12M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-101.3%

↓

Gross Margin

N/A

•

Debt/Equity

N/A

•

No hay histórico de precio usable para pintar el gráfico TradingView.

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2017–2025 · 8 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

—

FCF / Net income

—

Latest source

Provider fallback

Margin decomposition

Último año: revenue — · net income $-12.6M · FCF —

2017-FY → 2025-FY

Gross margin

—— pts

Operating margin

—— pts

Net margin

—— pts

FCF margin

—— pts

Metric	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017
Income Statement
Net Income	$-12.6M	$-12.6M	$-13.0M	$-14.3M	$-112.7M	$-37.1M	$-53.5M	$-28.1M	$-15.5M	$-15.2M
EBITDA	$-13.2M	$-13.2M	$-14.3M	$-15.5M	$-113.4M	$-37.4M	—	—	—	—
EPS	-1.93	-1.93	-2.35	-3.95	-67.99	-34.88	-50.61	-4.67	—	—
Cash Flow
Free Cash Flow	—	—	$-13.6M	$-12.3M	—	—	$-41.8M	$-26.7M	$-15.3M	—
Returns
ROE	-101.3%	-101.3%	-67.1%	-84.3%	-439.3%	-75.0%	-69.1%	-22.6%	30.2%	42.5%
Growth & Yield
EPS Growth	17.9%	17.9%	40.5%	94.2%	-94.9%	31.1%	-983.7%	—	—	—

Returns (%)